HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value.

AbstractOBJECTIVE:
Health economic models can assist policy-makers in determining the value of novel treatments from the viewpoint of society. In this context, value is defined as the benefit of treatment, given its cost. A new treatment for wet age-related macular degeneration (AMD), juxtascleral administration of anecortave acetate, 15 mg for depot suspension (Retaane), is now in a late-phase clinical trial. In a theoretical analysis, we sought to determine the cost at which this treatment might offer economic value to society, using incremental cost-effectiveness ratios (ICERs).
METHODS:
A series of 1-year cost-utility models was created for the investigational treatment and standard treatment (photodynamic therapy [PDT] with verteporfin [Visudyne]). Value to society was defined in terms of theoretical associated ICERs (in US dollars): $100,000 per quality-adjusted life-year (QALY), $50,000/QALY, $20,000/QALY and $0/QALY, the point of economic indifference. Models were created from the societal perspective and included a patient-derived utility assessment involving regression equations to estimate time trade-off preferences, event probabilities derived from a randomized clinical trial comparing the safety and efficacy of anecortave administration and PDT with verteporfin, decision analysis and relevant costing information.
RESULTS:
An ICER of $100,000/QALY would be associated with an anecortave cost of $3022/vial, an ICER of $50,000/QALY with an anecortave cost of $2986/vial and an ICER of $20,000/QALY with an anecortave cost of $2964/vial. The point of economic indifference between anecortave administration and standard therapy would occur with an anecortave cost of $2950/vial.
INTERPRETATION:
In theory, an anecortave cost of $2986/vial is associated with an ICER of $50,000/QALY, the threshold used by many health technology assessment and reimbursement agencies.
AuthorsSanjay Sharma, Jeff Bakal, Susan M Sharma, Dave Covert, Gaurav K Shah
JournalCanadian journal of ophthalmology. Journal canadien d'ophtalmologie (Can J Ophthalmol) Vol. 40 Issue 3 Pg. 369-77 (Jun 2005) ISSN: 0008-4182 [Print] England
PMID15947806 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
Topics
  • Clinical Trials, Phase III as Topic
  • Costs and Cost Analysis
  • Drug Costs
  • Drug Utilization Review (trends)
  • Humans
  • Macular Degeneration (drug therapy, economics)
  • Models, Economic
  • Photochemotherapy (economics)
  • Photosensitizing Agents (economics, therapeutic use)
  • Porphyrins (economics, therapeutic use)
  • Socioeconomic Factors
  • Verteporfin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: